GRANTING $16 MILLION ACROSS 56 RESEARCH PROJECTS WORLDWIDE
Since Canadian Researcher Dr. Ronald Worton co-discovered the gene for Duchenne, the average life expectancy of a child with Duchenne has increased from late teens to close to 30.
When Jesse's
Journey was
founded, there
were no clinical
trials targeting Duchenne and no
approved treatments.
Jesse Davidson
Post-Doctoral
Fellowships were
awarded to
researchers
focused on gene
therapy, making
significant
contributions to
this area of study.
Jesse's Journey
becomes the only
Canadian charity
to provide support
as a founding
partner of the
Canadian
Neuromuscular
Disease Registry
(CN DR), Canada's
first patient
database that
facilitates
research in
Duchenne.
Researchers
supported by
Jesse's Journey
prove the gene
responsible for
Duchenne can be
repaired.
Researchers
supported by
Jesse's Journey
identify a
sequence in the
dystrophin gene that is
essential for
helping muscle
tissues function-a
breakthrough
labelled as finding
a "needle in a
haystack".
Researchers supported by Jesse's Journey become the first to create a dystrophin "microgene'' that is improving muscle function in dogs and may soon be ready for clinical trials in patients.
Researchers supported by Jesse's Journey discover Duchenne is a stem cell disease which will lead to further drug targets for Duchenne.
Researchers supported by Jesse's Journey discover Duchenne is a stem cell disease which will lead to further drug targets for Duchenne.
More that 25 clinical trials targeting Duchenne are now underway involving boys at clinics across Canada.
Researchers supported by Jesse's Journey begin to utilize the CRISPR/Cas9 genome editing technology.
Researchers supported by Jesse's Journey conducted phase 1/11 clinical trial delivering myoblasts to Duchenne patients.
Jesse's Journey hits its highest funding year to date and, for the first time, grants $1 million dollars to clinical trials in Canada.
Jesse's Journey funds novel research focused on improving the delivery of gene therapies (supporting a high unmet need of the Duchenne population with point mutations), and funds the first grant toward patient care and sexual health.
Jesse's Journey funds novel research focused on improving the delivery of gene therapies (supporting a high unmet need of the Duchenne population with point mutations), and funds the first grant toward patient care and sexual health.
Jesse's Journey continues to exceed our number of granting applications each year, attracting research proposals from leading Duchenne researchers from all over the world.